Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Non-Current Debt (2024 - 2025)

Apellis Pharmaceuticals filings provide 2 years of Non-Current Debt readings, the most recent being $361.7 million for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Debt rose 0.61% year-over-year to $361.7 million, compared with a TTM value of $361.7 million through Dec 2025, up 0.61%, and an annual FY2025 reading of $361.7 million, up 0.61% over the prior year.
  • Non-Current Debt hit $361.7 million in Q4 2025 for Apellis Pharmaceuticals, roughly flat from $361.1 million in the prior quarter.
  • The five-year high for Non-Current Debt was $364.0 million in Q2 2024, with the low at $359.0 million in Q3 2024.